Interestingly, clinical samples from CRC patients resistant to cetuximab exhibited significantly higher SLC1A5 expression in IHC staining compared to those responsive to the treatment, suggesting the potential of SLC1A5 as a prognostic biomarker to predict chemo-response in CRC [214]. This evidence concerns the gene SLC1A5 and colorectal carcinoma.